Oncternal Therapeutics Faces Workforce Reduction Challenges: Potential Risks and Implications

TipRanksNov 8 14:01

Oncternal Therapeutics | 10-Q: Quarterly report

SECNov 7 05:32 · Announcements

Oncternal Therapeutics Has Been Granted U.S. Patent Number 12,128,026 Titled "Selective Androgen Receptor Degrader Ligands And Methods Of Use Thereof (For The Treatment Of Prostate Cancer)"

BenzingaOct 30 03:17

Express News | Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of Onct-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

BreakingsOct 22 21:00

Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Yahoo FinanceOct 22 21:00

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

BenzingaOct 15 20:08